Global Complex Regional Pain Syndrome (CRPS) Market Insights, Epidemiology and Market Forecast Report 2017-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total prevalent cases of CRPS, Total diagnosed prevalent cases of CRPS, Gender-specific diagnosed prevalent cases of CRPS, Age-specific diagnosed prevalent cases of CRPS, Type-specific diagnosed prevalent cases of CRPS, Severity-specific diagnosed prevalent cases of CRPS, and Total Treated Cases of CRPS scenario of CRPS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

CRPS Drug Chapters

Drug chapter segment of the CRPS report encloses the detailed analysis of CRPS developmental stage pipeline drugs. It also helps to understand the CRPS clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

CRPS Emerging Drugs

Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda

Soticlestat, also known as OV935 or TAK-935 is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. Soticlestat has completed (October 2020) Phase II (NCT03990649; EudraCT 2018-004750-21) of clinical trial in patients with CRPS.

BHV-5000: AstraZeneca/Biohaven Pharmaceutical

Biohaven Pharmaceutical's, BHV-5000 is an orally available, first-in-class, low-trapping, NMDA receptor antagonist. It is being developed for the treatment of neuropsychiatric disorders such as CRPS, Rett Syndrome and Major Depression. The company has already completed a Phase I trial in 2018 to evaluate its pharmacokinetic properties. This drug was reported to be well-tolerated.

Key Topics Covered:

1. Key Insights

2. Executive Summary of Complex Regional Pain Syndrome (CRPS)

3. SWOT Analysis

4. Epidemiology and Market Forecast Flow

5. Complex Regional Pain Syndrome (CRPS): Market Overview at a Glance

5.1. Total Market Share (%) Distribution of CRPS in 2017

5.2. Total Market Share (%) Distribution of CRPS in 2030

6. Complex Regional Pain Syndrome (CRPS): Disease Background and Overview

6.1. Introduction

6.2. Symptoms

6.3. Causes

6.4. Outcomes of CRPS

6.5. Clinical presentations

6.6. Natural course of CRPS

6.7. Classification

6.8. Pathophysiology

6.9. Diagnosis

6.9.1. Investigations

6.9.2. Imaging Techniques

6.9.3. Non-invasive imaging techniques

6.9.4. Thermography

6.9.5. Sudomotor Function Tests

6.9.6. Neurophysiological Tests

6.9.7. Examination

6.9.8. Differential diagnosis

6.10. Diagnostic Guidelines for CRPS

6.10.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA

6.10.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

6.10.3. Japanese CRPS diagnostic criteria

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Prevalent Cases of CRPS in the 7MM

7.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM

7.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM

7.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM

7.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in 7MM

7.3.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM

7.3.7. Treated cases of CRPS in the 7MM

7.4. The United States Epidemiology

7.5. EU-5 Epidemiology

7.6. Germany

7.7. France

7.8. Italy

7.9. Spain

7.10. The United Kingdom

7.11. Japan Epidemiology

8. Treatment and Management of CRPS

8.1. Treatment Guidelines

8.1.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA

8.1.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in CRPS Clinical Trials

12. Emerging Therapies

12.1. Key Cross Competition

12.2. Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.3. BHV-5000: AstraZeneca/Biohaven Pharmaceutical

12.3.1. Product Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

13. CRPS: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Outlook: 7MM

13.3. 7MM Market Size

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix

Companies Mentioned

• Ovid Therapeutics/Takeda
• AstraZeneca/Biohaven Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lh1kid.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900